why choose us

First received: August 31, 2023

Clinical Trial: Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations

Study Status: Completed

Recruit Status: RECRUITING

Condition: Immunosuppression

Study Type: INTERVENTIONAL


Official Title: Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations

Brief Summary: To determine whether providing a recombinant booster COVID-19 vaccine improves sustained humoral and cell-mediated immunogenicity against SARS-CoV-2 in immunosuppressed patients with Inflammatory Bowel Disease (IBD) and/or solid organ transplant recipients.120 participants will be enrolled and can expect to be on study for 6 months.

Read more